Brokerages predict that Orthofix International N.V. (NASDAQ:OFIX) will post $112.30 million in sales for the current quarter, Zacks reports. Two analysts have issued estimates for Orthofix International’s earnings. The lowest sales estimate is $111.40 million and the highest is $113.20 million. Orthofix International reported sales of $108.54 million in the same quarter last year, which indicates a positive year over year growth rate of 3.5%. The company is scheduled to report its next quarterly earnings report on Monday, February 26th.

According to Zacks, analysts expect that Orthofix International will report full-year sales of $112.30 million for the current financial year, with estimates ranging from $428.40 million to $430.30 million. For the next financial year, analysts forecast that the firm will report sales of $451.47 million per share, with estimates ranging from $446.50 million to $456.10 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Orthofix International.

Orthofix International (NASDAQ:OFIX) last released its quarterly earnings data on Monday, October 30th. The medical device company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.41 by $0.01. Orthofix International had a return on equity of 10.26% and a net margin of 0.33%. The company had revenue of $105.30 million during the quarter, compared to the consensus estimate of $100.67 million. During the same period last year, the company earned $0.36 EPS. Orthofix International’s revenue for the quarter was up 6.9% on a year-over-year basis.

OFIX has been the subject of several research analyst reports. TheStreet downgraded Orthofix International from a “b” rating to a “c+” rating in a report on Tuesday, October 31st. Zacks Investment Research cut Orthofix International from a “buy” rating to a “hold” rating in a research report on Wednesday, November 8th. BTIG Research set a $56.00 target price on Orthofix International and gave the stock a “buy” rating in a research report on Monday, October 30th. BidaskClub raised Orthofix International from a “hold” rating to a “buy” rating in a research report on Thursday, August 17th. Finally, Jefferies Group reissued a “buy” rating and issued a $55.00 target price (up from $50.00) on shares of Orthofix International in a research report on Thursday, August 10th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $54.42.

In other Orthofix International news, insider Bradley V. Niemann sold 6,956 shares of the firm’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $49.44, for a total value of $343,904.64. Following the transaction, the insider now directly owns 40,178 shares of the company’s stock, valued at $1,986,400.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Rice Doug sold 7,353 shares of the firm’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $49.46, for a total value of $363,679.38. Following the completion of the transaction, the chief financial officer now directly owns 44,743 shares in the company, valued at $2,212,988.78. The disclosure for this sale can be found here. Insiders sold 24,109 shares of company stock worth $1,220,840 over the last three months. Insiders own 5.60% of the company’s stock.

A number of large investors have recently made changes to their positions in the business. Oakview Capital Management L.P. purchased a new position in shares of Orthofix International during the 3rd quarter valued at about $12,756,000. Paradice Investment Management LLC purchased a new position in shares of Orthofix International during the 2nd quarter valued at about $6,642,000. River Road Asset Management LLC purchased a new position in shares of Orthofix International during the 2nd quarter valued at about $6,419,000. State Street Corp lifted its position in shares of Orthofix International by 27.0% during the 1st quarter. State Street Corp now owns 462,479 shares of the medical device company’s stock valued at $17,640,000 after buying an additional 98,212 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Orthofix International by 11.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 870,120 shares of the medical device company’s stock valued at $40,443,000 after buying an additional 90,349 shares in the last quarter. 94.61% of the stock is currently owned by institutional investors and hedge funds.

Shares of Orthofix International (NASDAQ OFIX) opened at $52.81 on Tuesday. Orthofix International has a twelve month low of $32.51 and a twelve month high of $54.73. The company has a market capitalization of $984.29, a PE ratio of 35.29, a P/E/G ratio of 2.68 and a beta of 0.14.

COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Expect Orthofix International N.V. (OFIX) Will Announce Quarterly Sales of $112.30 Million” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/05/zacks-analysts-expect-orthofix-international-n-v-ofix-will-announce-quarterly-sales-of-112-30-million.html.

Orthofix International Company Profile

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

Get a free copy of the Zacks research report on Orthofix International (OFIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Orthofix International (NASDAQ:OFIX)

Receive News & Ratings for Orthofix International N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International N.V. and related companies with MarketBeat.com's FREE daily email newsletter.